LAD1 Inhibitors
LAD1 inhibitors encompass a variety of chemical compounds that indirectly suppress LAD1's role in cell adhesion and migration by targeting different cellular signaling pathways and molecular mechanisms. PD 98059, LY 294002, and U0126 are inhibitors that act on the MAPK/ERK and PI3K/Akt pathways, crucial modulators of integrin signaling and cytoskeletal dynamics, which are essential for LAD1-mediated cell attachment and spreading. Similarly, Y-27632 and fasudil, as inhibitors of the ROCK pathway, lead to a reduction in stress fiber formation and focal adhesions, further diminishing the functional activity of LAD1 in maintaining cellular connections to the extracellular matrix. The impact on cell adhesion is also evident with the use of blebbistatin, which inhibits myosin II ATPase activity, and dasatinib, which inhibits Src family kinases, both leading to weakened cell-matrix interactions that are critical for LAD1's function.
In addition to these, SP600125, a JNK pathway inhibitor, and SB 203580, a p38 MAPK inhibitor, modulate the cellular response to stress and inflammation, ultimately affecting LAD1's role in the cellular adhesion and migration processes. Wortmannin, another PI3K inhibitor, parallels LY 294002 in disrupting cellular survival and adhesion signals, further contributing to the downregulation of LAD1 activity. Gö 6976, by inhibiting PKC, affects intracellular signaling that supports cell adhesion and migration, thereby indirectly limiting LAD1's function. Marimastat, although primarily targeting MMPs to prevent extracellular matrix degradation, can also influence the cellular adhesion landscape, potentially affecting LAD1-mediated interactions. Collectively, these inhibitors, through their targeted actions on various signaling pathways and cellular processes, serve to decrease the functional activity of LAD1, a protein essential for cell adhesion and integrity within the extracellular matrix.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
An MEK inhibitor that specifically blocks the activation of MAPK/ERK pathway. LAD1, as an adhesion molecule, is influenced by the cytoskeletal rearrangements and integrin signaling that are downstream of the MAPK/ERK pathway. Inhibition of this pathway can diminish the functional activity of LAD1 by altering integrin-mediated cell adhesion. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
A PI3K inhibitor that impairs the PI3K/Akt signaling pathway. This alteration can lead to reduced cell survival and adhesion signaling, indirectly diminishing LAD1's role in cell adhesion and migration. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $186.00 $707.00 | 88 | |
A ROCK inhibitor that modulates actin cytoskeleton dynamics and cell shape, which can indirectly decrease LAD1-mediated cell-matrix adhesion by affecting stress fiber formation and focal adhesion. | ||||||
(S)-(−)-Blebbistatin | 856925-71-8 | sc-204253 sc-204253A sc-204253B sc-204253C | 1 mg 5 mg 10 mg 25 mg | $72.00 $265.00 $495.00 $968.00 | ||
An inhibitor of myosin II ATPase activity, leading to impaired muscle contraction and cell motility. As LAD1 is involved in cell adhesion, the inhibition of myosin II can lead to diminished LAD1 function by destabilizing cellular attachments. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
A tyrosine kinase inhibitor that can inhibit Src family kinases. Src kinase activity is involved in the regulation of adhesion dynamics; therefore, dasatinib can indirectly lead to reduced LAD1-mediated cell-matrix interactions. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
A JNK inhibitor that can downregulate the JNK signaling pathway. JNK is involved in cellular processes such as apoptosis and cytoskeletal reorganization. Inhibition of JNK signaling can decrease LAD1 function by affecting cell adhesion and migration. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
A potent inhibitor of PI3K, wortmannin disrupts the PI3K/Akt signaling pathway, which can indirectly impair LAD1's role in cellular adhesion and migration processes. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
A p38 MAPK inhibitor that can reduce inflammatory responses and cellular stress signaling. By inhibiting p38 MAPK, which is involved in cytoskeletal dynamics and cell adhesion, SB 203580 can indirectly diminish LAD1-mediated cell attachment. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
An inhibitor of MEK1/2, which are upstream regulators of the ERK pathway. U0126 can decrease LAD1's adhesion functions by affecting the signaling pathways that regulate integrin activation and cell attachment. | ||||||
Gö 6976 | 136194-77-9 | sc-221684 | 500 µg | $227.00 | 8 | |
A protein kinase C (PKC) inhibitor, which can diminish intracellular signaling related to cell adhesion and migration. By inhibiting PKC, Gö 6976 can indirectly affect LAD1 function in maintaining cell-matrix interactions. | ||||||